AB-2004
Phase 2- Indications
- Autism Spectrum Disorder
Company intelligence / Profile preview
Axial Therapeutics
Woburn, Massachusetts, United Statesaxialtx.com ↗
- Ownership
- Private
- Employees
- ~23
- Development stage
- Phase 2
01
Overview
Completed enrollment in Phase 2b TAPESTRY Autism Study for AB-2004 with 156 children and adolescents with autism. Data anticipated in Q1 2024. AB-2004 was safe and well-tolerated in Phase 1b/2a clinical trial with no drug-related serious adverse events. IND-enabling studies ongoing for AX-5006 for Parkinson's disease to support Phase 1 clinical trial initiation in 2024.
- Therapeutic areas
- GastroenterologyOncologyPsychiatryNeurology
- Modalities
- Small moleculesgut-restricted small molecule therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
The Michael J. Fox Foundation for Parkinson's Research
Beyond the preview
Go deeper on Axial Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axial Therapeutics.